Fennec Pharmaceuticals Inc.
FENC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001211583
In the last 90 days, Fennec Pharmaceuticals Inc. insiders filed 0 open-market purchases and 5 sales; 105 institutions reported holding it in 13F filings for Q2 2026, worth $175.1M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Fennec Pharmaceuticals Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 39 | 32 | −7 |
| Shares | 12.1M | 11.6M | −429.3K (−3.6%) |
| Value | $88.0M | $109.7M | +$21.7M (+24.6%) |
New holders (3)
Institutions that held Fennec Pharmaceuticals Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Belvedere Trading LLC | 17,790 | $155.0K | 0.04% |
| Ancora Advisors, LLC | 6,000 | $57.0K | 0.00% |
| Group One Trading, L.P. | 1,600 | $15.0K | 0.00% |
Sold out (10)
Institutions that held Fennec Pharmaceuticals Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Gsa Capital Partners LLP | 68,724 | $501.0K |
| Tibra Equities Europe Ltd | 46,300 | $338.0K |
| Jane Street Group, LLC | 24,278 | $177.0K |
| Renaissance Technologies LLC | 20,284 | $148.0K |
| JPMorgan Chase & Co | 20,021 | $146.0K |
| ExodusPoint Capital Management, LP | 17,115 | $125.0K |
| Virtu Financial LLC | 13,454 | $98.0K |
| Deutsche Bank AG | 3,068 | $22.0K |
| New York State Common Retirement Fund | 198 | $1.00K |
| Cutler Group LP | 100 | $0 |